Detailed Narrative
Strong Q2 FY26 Financial Performance
Jeena Sikho reported robust Q2 FY26 results, with revenue from operations reaching Rs. 190 crores, marking a 66% year-on-year and 9% quarter-on-quarter growth. PAT surged to Rs. 59 crores, up 121% YoY and 15% QoQ, while EBITDA grew by 129% YoY and 17% QoQ to Rs. 92 crores, achieving a healthy 48% margin. Management highlighted over-delivery on previous commitments and strong performance in both product (78% YoY growth) and services segments.
Aggressive Bed Capacity Expansion and Utilization Focus
The company rapidly expanded its total bed capacity to 2,802, achieving its FY26 year-end target of 2,850 beds within six months. Currently, 2,200 beds are operational, an increase of 600 beds in six months. Management aims to increase bed occupancy from the current 57% to 80% within the next six to eight months, and plans to add another 200-300 beds in the next six months, targeting 3,000-3,100 beds by FY26 end. The long-term vision is to reach 7,000-10,000 beds in three to five years.
Product Portfolio Expansion and OTC Business Growth
Jeena Sikho is aggressively expanding its product pipeline, planning to launch 15 to 20 new products in the next six to twelve months, with 10 products specifically targeted for launch by the end of FY26. The OTC business has shown promising early trends, generating Rs. 2.25 crores in online sales last month. The company is in talks with a large distributor network (Entero, with 1 lakh pharmacies) to expand reach, targeting Rs. 300-500 crores in OTC and product marketing turnover in the next one to two years, with a PAT margin target of 18-22% for OTC products.
Strategic Partnership with Chandan Diagnostic
A significant tie-up with Chandan Diagnostic is expected to drive footfall and enhance services. Chandan, with 40 lakh privilege card holders, will offer free basic blood tests (ESR, uric acid, CBC, lipid profile, LFT, RFT, thyroid) to Jeena Sikho's customers, and their NABL-accredited labs will support health insurance claims. Jeena Sikho will offer up to 30% cashback to patients on medicines and hospital admissions, leveraging Chandan's network and diagnostic capabilities. Chandan is investing Rs. 10 crores and more into setting up diagnostic centers, including full-fledged VIP centers with advanced imaging.
Cautious Approach to Government Business
Management expressed a cautious stance on expanding government business (RGHS/CGHS) due to concerns about payment delays and a lengthy TAT (turnaround time) of two and a half months with the current government portal. The focus remains on the private sector and health insurance segments, which offer better cash flow and operational efficiency. A trial will be conducted once a new government portal is launched to assess payment timelines before aggressive expansion.
International Expansion and Franchise Model
Jeena Sikho has initiated international expansion, with operations already profitable in Nepal and Dubai (Abu Dhabi). The company is also planning to launch a franchise model for hospitals, aiming to open at least 50 new franchise hospitals next month without direct investment, focusing on a revenue-sharing model. This strategy is intended to accelerate growth and market penetration across India and internationally.
Accounting Changes and Credibility
The company migrated to Ind-AS and engaged Grant Thornton for accounting, leading to some restatements and adjustments in financial reporting. Management emphasized that this move, along with the GT stamp, addresses previous doubts about the company's profitability and reinforces its authenticity as a genuine company.